Xin Li
University of Houston
50 Papers
71 Citations
Xin Li is an academic researcher from University of Houston. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 15, co-authored 36 publications. Previous affiliations of Xin Li include Baylor College of Medicine & Shandong University.
Chat about Author
Papers
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li,Yongcheng Song +1 more
TL;DR: Proteolysis-targeting chimera PROTACs targeting ~ 50 proteins, many of which are clinically validated drug targets, have been successfully developed with several in clinical trials for cancer therapy.
Targeting MDM2 for novel molecular therapy: Beyond oncology
TL;DR: Recent findings related to the roles of MDM2 in the pathogenesis of several nonmalignant diseases, the therapeutic potential of its downregulation or inhibition, and its use as a biomarker are paid special attention.
80
Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ
TL;DR: A review of the function and dynamic behaviors of Filamentous temperature-sensitive protein Z, a prokaryotic cytoskeleton protein, and the known natural and synthetic inhibitors of FtsZ.
72
Design, synthesis and antibacterial activity of cinnamaldehyde derivatives as inhibitors of the bacterial cell division protein FtsZ.
TL;DR: In an attempt to discover potential antibacterial agents against the increasing bacterial resistance, novel cinnamaldehyde derivatives as FtsZ inhibitors were designed, synthesized and evaluated for their antibacterial activity against nine significant pathogens using broth microdilution method, and their cell division inhibitory activity against four representative strains.
72
Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins
Xin Li,Yongcheng Song +1 more
TL;DR: In this article, a review summarizes the biological functions, biochemistry, structure and inhibition of the critical PPIs involving MLL1 and its fusion partner proteins, and challenges and perspectives of drug discovery targeting these PPIs for the treatment of MLL-1-r leukemia are discussed.